

Via Facsimile  
Date of Deposit: July 22, 2004

Attorney Docket No: 21629-001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Hoffman, Andrew  
SERIAL NUMBER: 09/616,483 EXAMINER: Patel, Mital B.  
FILING DATE: July 14, 2000 ART UNIT: 3761  
FOR: DRUG DELIVERY DEVICE FOR ANIMALS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION OF PRIOR INVENTION UNDER 37 C.F.R. § 1.131**

I, Ingrid A. Beattie, declare:

1. I am the patent counsel to Tufts University, assignee of the above-referenced patent application.
2. I submit herewith a copy of billing records to establish diligence in working to constructive reduction to practice of the claimed invention from a time prior to the May 16, 2000 effective filing date of Barney et al. to the July 14, 2000 filing date of the above-referenced patent application.
3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

IA Beattie  
Declarant's Signature  
Full Name of Declarant: Ingrid A. Beattie

July 22, 2004  
Date

Attachments:  
Exhibit: Invoice # 8147170

TRA 1942014v1

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111

TUFTS UNIVERSITY  
THOMAS J. MCVARISH  
OFFICE FOR TECHNOLOGY AND INDUSTRY COLLABORATION  
136 HARRISON AVENUE  
BOSTON, MA 02111

August 10, 2000  
Invoice # 8147170  
Client # 21629

FOR PROFESSIONAL SERVICES RENDERED THROUGH JULY 31, 2000

RE: 09/616483 DRUG DELIVERY DEVICE FOR ANIMALS

21629-001

05/00 Review prior art.	I A BEATTIE
05/00 Meeting with Dr. Hoffman; review prior art references; work on application.	I A BEATTIE
06/15/00 Work on application.	I A BEATTIE
06/25/00 Work on application.	I A BEATTIE
06/27/00 Work on application.	I A BEATTIE
06/28/00 Work on application.	I A BEATTIE
06/30/00 Work on application.	I A BEATTIE
07/03/00 Work on application.	I A BEATTIE
07/08/00 Work on application; send claims to client.	I A BEATTIE
07/10/00 Work on application.	I A BEATTIE
07/12/00 Telephone conference with F. Toneguzzo regarding claim strategy.	I A BEATTIE

DUFTS UNIVERSITY  
CLIENT NUMBER: 21629  
INVOICE NO.: 8147170

August 10, 2000 PAGE 2

07/14/00 Work on and file  
application; telephone  
conference with Dr. Hoffman.

I A BEATTIE

07/25/00 Attention to email form Dr.  
Hoffman regarding status of  
patent application.

I A BEATTIE

TOTAL MATTER SERVICES:

MATTER EXPENSE SUMMARY

Reprographics  
Evening/WP Secretarial Time  
Postage  
Telephone  
Filing Fees - -FOR- 7/14/00 (USPTO/UTILITY  
APPLICATION)

TOTAL MATTER EXPENSES:

TOTAL MATTER FEES AND EXPENSES:

**MINTZ LEVIN  
COHN FERRIS  
GLOVSKY AND  
POPEO PC***Boston**New York**Reston**Washington**London**One Financial Center  
Boston, Massachusetts 02111  
617 542 6000  
617 542 2241 fax  
www.mintz.com**Fax Cover Sheet***DATE:** July 22, 2004**FROM:** Ingrid A. Beattie, Ph.D., J.D.  
*Direct Dial 617 348 1838  
iabeattie@mintz.com***TO:**

NAME	BUSINESS #	FAX #
Examiner Mital B. Patel		703 746-3388

**MESSAGE:****Applicant:** Hoffman, Andrew  
**U.S. Serial No.:** 09/616,483  
**Filing Date:** July 14, 2000  
**Title:** DRUG DELIVERY DEVICE FOR ANIMALS

Attached, please find the following documents:

1. Supplemental Response;
2. Declaration of Prior Invention of Andrew Hoffman;
3. Declaration of Prior Invention of Ingrid A. Beattie, Ph.D., J.D.;
4. Invoice No. 8147170

*1. Exhibit A (Hoffman  
Decl.)  
3 pages*

Please call me with any questions.

Ingrid A. Beattie, Ph.D., J.D.

*2. Exhibit B (Hoffman  
Decl.)  
4 pages***We are sending a total of 8 pages, including this cover sheet.**

Please call us at 617 654 8024, if you experience any problems.

STATEMENT OF CONFIDENTIALITY  
THE INFORMATION CONTAINED IN THIS FAX IS INTENDED FOR THE EXCLUSIVE USE OF THE ADDRESSEE AND MAY CONTAIN  
CONFIDENTIAL OR PRIVILEGED INFORMATION. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT  
ANY FORM OR DISSEMINATION OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF THIS FAX WAS SENT IN ERROR,  
PLEASE IMMEDIATELY NOTIFY US BY PHONE.

11:57

TUFTS ASSOC. PROVOST/RES.

MAINLY


1. NSES

517 636 2917

P.08/11

A HOFFMAN

Fig 1



- ① SPACER HOLDING CHAMBER
- ② OPENING WHICH FITS OVER NARIS (CIRCULAR OPENING)
- ③ SOFT RUBBER-LIKE INTERFACE
- ④ INSPIRATORY VALVE ( $4.5 \text{ L/min H}_2\text{O}$ )
- (4.5) UNIDIRECTIONAL FLOW triggered by inspiration


NOTE: EXPIRATORY FLOW OCCURS THROUGH OPPOSITE NOSTRIL OR BY REMOVING DEVICE

- ⑤ CLEAR SYNTHETIC PLASTIC MATERIAL - PREFERABLY NON-ELECTROSTATIC.
- ⑥ APPROXIMATE MINIMUM ANGLE - ALLOWS PERSON TO STAND IN VARIOUS POSITIONS FOR DELIVERY ( $45^\circ$  is recommended)
- ⑦ LOW RESISTANCE INTAKES ( $4.05 \text{ L/min H}_2\text{O}$ )
- ⑧ PMDI, DPI or other DRUG DELIVERY SYSTEM UPSCALED IN SIZE FOR HORSES.
- ⑨ DIMENSIONS COULD VARY

- ⑩ EXAMPLES OF PER-ACTUATION DOSES

ALBUTEROL 450 mcg, 200 mcg  
 IPRAATROPUM-Br 90 mcg  
 FLUTICASONE 1.1 mg, 500 mcg  
 BELLONEMASQUE 250 mcg - SUTIN

Fig 2






11.0 angled interface  
allows for a variety  
of positions  
during administration  
of inhaler  
drugs.

Exhibit A (2 of 3)

Alt Hoffman

Fig 3  
FLOW OF AEROSOL  
DURING INSPIRATION






rubber  
for compression

In average 50kg  
ad H horse

Expected Flows:

tidal breathing -	
PIF	2 liters/sec
PEF	2 L/sec
TV	5-8 L
MV	100 L/min
Ti	1.5 sec
Te	2.5 sec



1-3 different  
angles of  
interfacing  
with  
external  
nostrils.

Andrew Hoffman

**Compact inhalation drug delivery device for animals**

Dr. Andrew Hoffman  
Tufts University School of Veterinary Medicine  
200 Westboro Road  
North Grafton, MA, 01536, USA

Background

Small airway diseases (i.e. including small airway inflammatory disease, heaves, chronic obstructive pulmonary disease) are prevalent causes of exercise intolerance, cough, and asthma-like attacks in horses (Hoffman 1997). These clinical signs are thought precipitated by progressive allergic reactions to dust found in hay and in the environment, but the cause is not always identified. Traditional management includes minimizing the horse's exposure to dust and conventional hay, bronchodilator treatment for immediate relief, steroid treatment to reduce inflammation and bring about remission, and long-term preventative control with inhaled anti-inflammatories (Hoffman 1993, 1997, 1999, Rush 1998, 1999, Ammann 1998). More recently, there are studies that demonstrate the efficacy of inhaled medications for treatment of small airway diseases (Hoffman 1993, Tesarowski 1994, Derksen 1996). The advantage of using aerosols for treatment over using oral or parenteral drugs, is the fact that aerosols treat the airways directly and topically, with little systemic (i.e. blood) absorption (Hoffman 1997). As a result, there are little to no side effects caused by aerosols, yet a potent effect on the target tissues, the airways.

To deliver aerosols to the lung without voluntary cooperation from a horse is a special consideration. To date, two methods have been developed. The first method (Hoffman 1993, Tesarowski 1994) involves the placement of a facemask, with one

Exhibit B (1 of 4)



unidirectional inhalation valve mounted on the proximal end, and two exhalation (i.e. exit) valves mounted on the side of the mask ("Equine Mask with MDI Adapter" US Patent 5,954,049, Sept 21, 1999). A spacer chamber ("MDI Adapter") is placed over the inhalation valve, allowing for the horse to inhale the aerosol from the chamber. This device is most suitable for delivery of aerosols from pressurized canisters (pMDI). Effectively, this device prevents drug, actuated into the chamber, from being exhaled out the chamber. This permits unidirectional flow of the drug from the chamber, to the mask, and finally the respiratory system via the nasal passages, without the need for coordinating the timing of pMDI actuation and inhalation. In summary, the advantage of this device is that it offers "virtual breath actuation", is easily cleaned, and only requires that a mask is placed on the muzzle of the animal. A second system that has been patented recently ("Attachment for Aerosol Device for Large Animals and Method of Use", US Patent 5,666,948, Sept 16, 1997) requires that the actuation of the pMDI is coordinated with inspiration (Derksen 1996). The drug is actuated through a bulb and stem, which acts like a holding chamber, and is placed within one nostril, pointing distally. The drug is inhaled with air that flows through the bulb-stem chamber during inhalation. The advantage of the latter system may be greater deposition, since the external nares are bypassed. The disadvantage of the latter system is the need to place the device in the nose, and the tendency for asynchrony between the actuation of the cannister and the animal's inhalation, resulting in drug wastage.

A device that does not require insertion in the nose is desirable from the perspective of the animal, since nasal insertion is irritating, and the owner, that is upset having to place this device in their animal's nose, is also required to perform more

Exhibit B (2 of 4)

rigorous restraint. Furthermore, not all horses will accept this device initially. A device that is more compact than Patent 5,954,049 would also be advantageous, since carrying the device on trail rides, and storage space can be limited. The following description is of a device that combines the advantages of compactness and does not require insertion into the nose, while preserving the desired effect. Preliminary studies with external nasal delivery of bronchodilator aerosols in horses have demonstrated beneficial effects as for the mask device (unpublished data).

#### Description of the inventions (Devices 1 and 2)

The devices are composed of clear solid plastic or similar material, with minimal electrostatic properties. There are two possible arrangements envisaged. Device 1 is larger and incorporates a holding chamber. The size and features of Device 1 are approximately depicted in Fig 1. Device 1 is applicable to delivery of pMDI aerosols, since these require a spacer chamber for holding the drug in a cloud suspension prior to inhalation. A one-way valve is used to separate the holding chamber from a patient interface, which is angled to allow the user to stand off to the side, yet minimize the angle of delivery and therefore maximize deposition in the respiratory system. Device 1 has small holes on the proximal (pMDI) end, which allow air to flow through the chamber to evacuate the drug into the respiratory system during inhalation. On the distal end, the interface mushrooms to cover the nare on one side (either side) of the horse. The circular opening allows for a number of angles of attachment (Fig 2 and 3). The interface may have a soft rubber or latex boot for comfort and better conformation to the individual's shape. The inspiratory valve creates very little resistance ( $< 1 \text{ cm H}_2\text{O}$ ), to

Exhibit B (3 of 4)

afford maximal opening during inspiration. Expiratory flow is through the opposite nostril, so the inhaler can stay on the face as long as desired without interruption of breathing or drug deliveries. Device 1 could be used for delivery of dry powders or flow-through powders or flow-actuated aerosols of any type.

The second device (Device 2) is one that does not require a holding (i.e. spacer) chamber, and therefore is a collapsed version of Device 1. There is no inhalation valve, since the drug is swept with flow through the drug cannister. The drug cannisters used must possess this flow-through characteristic. This could apply to dry powder or propellant-based flow-through drug cannisters. There is no need for holes in the proximal end to accommodate flow in Device 2, since it is desirable to divert flow through the drug cannister. Device 2 is simply pressed against the nares, and with the next inhalation, a dose of the drug exits the cannister, into a short plastic interface space, and quickly from there into the horse during inhalation. This can be repeated on the next inhalation without delay. Again exhalation can be achieved through the opposite nostril, or by removing the device. Device 2 is super compact, and highly efficient, since it requires only normal breathing and no drug is wasted in a holding chamber. As there is no significant delay in delivery (i.e. the drug is delivered directly from cannister to patient), there would be little chance of losing drug to evaporation or environmental degradation. The horse can not exhale through the chamber, since there is no flow permitted in this direction.

The devices described here are not limited to the designs in this description, in that there can be variation as to size, angulation of the interface, materials, and dimensions. Furthermore, their use would not be limited to use in horses.

Exhibit B (4 of 4)